Total Payments
$46,720
2024 Payments
$1,094
Companies
66
Transactions
645
Medicare Patients
770
Medicare Billing
$91,853
Payment Breakdown by Category
Other$18,660 (39.9%)
Food & Beverage$10,128 (21.7%)
Travel$8,962 (19.2%)
Consulting$8,410 (18.0%)
Education$559.92 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,660 | 5 | 39.9% |
| Food and Beverage | $10,128 | 605 | 21.7% |
| Travel and Lodging | $8,962 | 15 | 19.2% |
| Consulting Fee | $8,410 | 3 | 18.0% |
| Education | $559.92 | 17 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23,761 | 74 | $0 (2024) |
| Exact Sciences Corporation | $8,671 | 3 | $0 (2023) |
| Advanced Accelerator Applications | $3,800 | 2 | $0 (2019) |
| Celgene Corporation | $1,466 | 20 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $982.68 | 74 | $0 (2024) |
| PFIZER INC. | $846.04 | 72 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $616.48 | 31 | $0 (2024) |
| Merck Sharp & Dohme LLC | $608.55 | 36 | $0 (2024) |
| Janssen Biotech, Inc. | $586.94 | 30 | $0 (2024) |
| Astellas Pharma US Inc | $576.21 | 28 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,094 | 58 | Janssen Biotech, Inc. ($150.88) |
| 2023 | $10,025 | 76 | Exact Sciences Corporation ($8,671) |
| 2022 | $1,408 | 79 | Astellas Pharma US Inc ($274.70) |
| 2021 | $1,297 | 73 | Astellas Pharma US Inc ($164.68) |
| 2020 | $1,437 | 73 | Novartis Pharmaceuticals Corporation ($372.80) |
| 2019 | $4,235 | 85 | Advanced Accelerator Applications ($3,000) |
| 2018 | $1,319 | 90 | Novartis Pharmaceuticals Corporation ($194.86) |
| 2017 | $25,904 | 111 | Novartis Pharmaceuticals Corporation ($22,853) |
All Payment Transactions
645 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $26.86 | General |
| Category: Oncology | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: Iron Deficiency Anemia | ||||||
| 11/26/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $23.73 | General |
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $3.90 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $3.30 | General |
| Category: Oncology | ||||||
| 09/23/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: Oncology | ||||||
| 09/16/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $22.81 | General |
| Category: Oncology | ||||||
| 09/10/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $20.85 | General |
| 09/03/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: Oncology | ||||||
| 08/27/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $13.96 | General |
| Category: Iron Deficiency Anemia | ||||||
| 08/21/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $18.35 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Oncology | ||||||
| 08/13/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $19.16 | General |
| 08/06/2024 | Azurity Pharmaceuticals, Inc. | VIVIMUSTA (Drug) | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: Oncology | ||||||
| 07/29/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: ONCOLOGY | ||||||
| 07/23/2024 | Genentech USA, Inc. | Gazyva (Biological), Venclexta | Food and Beverage | In-kind items and services | $27.40 | General |
| Category: BioOncology | ||||||
| 07/17/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 181 | 266 | $33,302 | $21,271 |
| 2022 | 5 | 204 | 298 | $39,296 | $26,276 |
| 2021 | 5 | 199 | 292 | $34,217 | $23,030 |
| 2020 | 3 | 186 | 295 | $31,550 | $21,277 |
Total Patients
770
Total Services
1,151
Medicare Billing
$91,853
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 101 | 138 | $14,757 | $9,114 | 61.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 78 | $11,856 | $8,032 | 67.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $2,535 | $1,771 | 69.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $2,754 | $1,694 | 61.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 20 | $1,400 | $659.82 | 47.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 48 | 101 | $15,352 | $10,439 | 68.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 94 | 135 | $14,524 | $9,132 | 62.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 35 | 35 | $6,410 | $4,719 | 73.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $2,080 | $1,537 | 73.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 11 | 11 | $930.00 | $448.44 | 48.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 54 | 109 | $14,246 | $10,396 | 73.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 90 | 128 | $12,071 | $7,023 | 58.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 31 | 31 | $5,460 | $3,970 | 72.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 13 | 13 | $1,690 | $1,347 | 79.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 11 | 11 | $750.00 | $294.26 | 39.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 64 | 142 | $16,580 | $11,663 | 70.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 95 | 126 | $10,515 | $6,405 | 60.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 27 | 27 | $4,455 | $3,209 | 72.0% |
About Dr. Dane Dickson, MD
Dr. Dane Dickson, MD is a Hematology & Oncology healthcare provider based in Rexburg, Idaho. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1669497194.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dane Dickson, MD has received a total of $46,720 in payments from pharmaceutical and medical device companies, with $1,094 received in 2024. These payments were reported across 645 transactions from 66 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($18,660).
As a Medicare-enrolled provider, Dickson has provided services to 770 Medicare beneficiaries, totaling 1,151 services with total Medicare billing of $91,853. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Rexburg, ID
- Active Since 07/13/2006
- Last Updated 01/24/2008
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1669497194
Products in Payments
- Cologuard Collection Kit (Device) $8,671
- LUTATHERA (lutetium Lu 177 dotatate) (Drug) $800.00
- OPDIVO (Biological) $792.17
- KEYTRUDA (Biological) $573.71
- EXJADE (Drug) $350.00
- Lenvima (Drug) $304.00
- IBRANCE (Drug) $273.84
- PADCEV (Drug) $232.29
- IMBRUVICA (Drug) $199.02
- AFINITOR (Drug) $195.45
- DARZALEX (Biological) $173.50
- TIBSOVO (Drug) $169.83
- Alecensa (Biological) $167.63
- BOSULIF (Drug) $164.90
- Enhertu (Drug) $160.69
- GILOTRIF (Drug) $155.14
- PROMACTA (Drug) $154.17
- Udenyca (Biological) $151.14
- CALQUENCE (Drug) $133.50
- XTANDI (Drug) $133.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.